fipaxalparant

Fipaxalparant (SAR100842) is a selective, orally available small molecule antagonist of lysophosphatidic acid receptor 1 (LPA1). It was developed as a potential treatment for diffuse cutaneous systemic sclerosis (dcSSc), targeting the LPA pathway implicated in tissue fibrosis. Preclinical and clinical studies have shown that SAR100842 inhibits LPA-induced signaling and gene expression associated with fibrosis. In phase 2a clinical trials, it demonstrated an acceptable safety profile and moderate efficacy in reducing skin thickness and fibrotic biomarkers in patients with early dcSSc. The drug engages its target effectively but did not show statistically significant differences versus placebo on primary efficacy endpoints; further studies are needed to confirm its therapeutic benefit[1][2][4][5][6][7].

Other names

fipaxalparant